Natasha Bahri, MD

CLINICAL INSTRUCTOR

Publications

  1. Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma. Journal of hematology & oncology 2021. PMID: 34404440


  2. Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements. PloS one 2020. PMID: 32866200


  3. Martinez-Lopez J, Wong SW, Shah N, Bahri N, Zhou K, Sheng Y, Huang CY, Martin T, Wolf J. Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma. Blood advances 2020. PMID: 32706892


  4. Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. Blood advances 2020. PMID: 32433744


  5. Tsuang A, Menon NR, Bahri N, Geyman LS, Nowak-Wegrzyn A. Risk factors for multiple epinephrine doses in food-triggered anaphylaxis in children. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2018. PMID: 29940309